YM BIOSCIENCES USA ENROLLS FIRST PATIENT IN PHASE II TRIAL OF NIMOTUZUMAB IN CHILDREN WITH INOPERABLE, RECURRENT BRAIN CANCER MISSISSAUGA, ON...
YM BIOSCIENCES REPORTS SECOND QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS MISSISSAUGA, ON, Feb. 7 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
News release via Canada NewsWire, Toronto 416-863-9350 Attention Business Editors: YM BIOSCIENCES SHAREHOLDING IN COMPANY MISSISSAUGA, ON, Jan...
YM BioSciences provides update on AeroLEF(TM) clinical development program MISSISSAUGA, ON, Jan. 17 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX:...
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL MISSISSAUGA, ON, Dec. 20 /CNW/ - YM BioSciences...
YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS MISSISSAUGA, ON, Nov. 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
YM Biosciences announces adoption of renewed Shareholders' Rights Plan MISSISSAUGA, ON, Oct. 22 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM...
YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS MISSISSAUGA, ON, Oct. 11 /CNW/ - YM BioSciences Inc...
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS MISSISSAUGA, ON, Sept. 24 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BIOSCIENCES NOTICE OF CONFERENCE CALL TO ANNOUNCE FOURTH QUARTER AND YEAR-END FISCAL 2007 FINANCIAL RESULTS MISSISSAUGA, ON, Sept. 20 /CNW/...
YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION Data Presented at the...
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer...
YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER...
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26 MISSISSAUGA, ON, Aug. 17 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an...
ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.